Orion Stock – Fundamental Analysis Solide

Orion: KGV 28.88 · Dividend yield 1.75 % · FScore Solide · As of 11/11/2026

Orion: KGV 28,9 · Dividendenrendite 1,8 % · FScore 65 (Solide) · Stand: 11.11.2026

Price
102.80
11/11/2026
Oct 1996
Nov 2026

Fundamental Data & Ratios (Balance sheet update: 2/17/2026)

Balance Sheet Total Assets 2.01 bn Equity Ratio 63.91 %
Balance Sheet Total Equity 1.28 bn ROA 24.89 %
Cashflow Capital Expenditures -97.60 m P/FCF 65.98
Cashflow Free Cash Flow 219.20 m – –
Cashflow Operating Cash Flow 316.80 m P/CF 45.65
Income Earnings per Share (diluted) 3.56 Div. Yield 1.75 %
Income Net Income 500.30 m P/E 28.88
Income Shares Outstanding 140.69 m P/B 11.26
Income Total Revenue 1.89 bn P/S 7.65

Ratios calculated on: 11/11/2026

Similar Companies

Company P/E Dividend Yield FScore
Chugai Pharmaceuticals Co., Ltd. 27.10 3.81 % Solide
Takeda Pharmaceutical Co Ltd 97.62 2.83 % Solide
Otsuka Holdings Co., Ltd. 18.91 1.00 % Solide
Daiichi Sankyo Co Ltd 17.76 2.23 % Schwach
Astellas Pharma Inc 92.93 2.72 % Solide
Shionogi & Co., Ltd. 15.25 1.87 % Solide
Eisai Co., Ltd. 30.66 3.21 % Solide
Kyowa Hakko Kirin Co., Ltd. 19.53 2.48 % Solide
Eli Lilly and Company 62.55 0.42 % Solide
Novo-Nordisk A/S 11.85 4.27 % Solide

Ratio History (10 Years)

Year P/E Dividend Yield Equity Ratio
2016 20.04 4.38 % 56.80 %
2017 12.58 5.85 % 60.32 %
2018 14.39 6.73 % 64.40 %
2019 13.78 4.57 % 67.42 %
2020 21.68 4.87 % 75.25 %
2021 19.93 4.86 % 65.55 %
2022 33.71 3.30 % 67.14 %
2023 14.55 4.17 % 60.40 %
2024 26.68 3.89 % 61.87 %
2025 26.84 2.58 % 61.69 %
2026 28.88 1.75 % 63.91 %

Company Description

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease.

Advanced Analysis Features

Additional comparison and history views are available after login.

Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.orion.fi
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown. Learn more